

Jesús Rodríguez-Baño

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/829253/publications.pdf>

Version: 2024-02-01

398
papers

24,466
citations

9786

73
h-index

11052

137
g-index

453
all docs

453
docs citations

453
times ranked

23493
citing authors

#	ARTICLE	IF	CITATIONS
1	Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 550-557.	6.0	62
2	Role of inorganic phosphate concentrations in inÂvitro activity of fosfomycin. <i>Clinical Microbiology and Infection</i> , 2022, 28, 302.e1-302.e4.	6.0	1
3	Association between rectal colonisation by <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>K. pneumoniae</i> and mortality: a prospective, observational study. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 476-482.	2.2	4
4	ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238.	6.0	103
5	Higher prevalence of CTX-M-27-producing <i>Escherichia coli</i> belonging to ST131 clade C1 among residents of two long-term care facilities in Southern Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 335-338.	2.9	3
6	Impact of early interferon-Î² treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112572.	5.6	8
7	Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant <i>Escherichia coli</i> Bacteremic Urinary Tract Infections. <i>JAMA Network Open</i> , 2022, 5, e2137277.	5.9	28
8	ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply. <i>Clinical Microbiology and Infection</i> , 2022, , .	6.0	1
9	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) TJ ETQq1 1 0.784314 rg3E4 Overl	6.0	14
10	Inappropriate use of ivermectin during the COVID-19 pandemic: Primum non nocere!. <i>Clinical Microbiology and Infection</i> , 2022, , .	6.0	7
11	Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1057-1065.	6.0	33
12	Prediction models in CMI. <i>Clinical Microbiology and Infection</i> , 2022, 28, 311-312.	6.0	6
13	Association between Timing of Colonization and Risk of Developing <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infection in Hospitalized Patients. <i>Microbiology Spectrum</i> , 2022, 10, e0197021.	3.0	4
14	Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. <i>Frontiers in Immunology</i> , 2022, 13, 860891.	4.8	11
15	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. <i>Microorganisms</i> , 2022, 10, 1021.	3.6	13
16	Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to <i>Staphylococcus aureus</i> : a multinational matched case-control study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1359-1366.	6.0	4
17	<i>Pseudomonas aeruginosa</i> Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Developmentâ€”Results from the PRO-BAC Cohort. <i>Antibiotics</i> , 2022, 11, 707.	3.7	1
18	Extendedâ€”spectrum Î²-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	5

#	ARTICLE	IF	CITATIONS
19	Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> : a Multicenter Cohort Study from the PROBAC Project. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	3
20	An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales. <i>Clinical Infectious Diseases</i> , 2021, 73, e4475-e4483.	5.8	2
21	Epidemiologic changes in bloodstream infections in Andalucía (Spain) during the last decade. <i>Clinical Microbiology and Infection</i> , 2021, 27, 283.e9-283.e16.	6.0	15
22	Efficacy of β -lactam/ β -lactamase inhibitors to treat extended-spectrum β -lactamase-producing <i>Enterobacterales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). <i>Transplant Infectious Disease</i> , 2021, 23, e13520.	1.7	10
23	Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. <i>Clinical Microbiology and Infection</i> , 2021, 27, 228-235.	6.0	67
24	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). <i>Clinical Microbiology and Infection</i> , 2021, 27, 244-252.	6.0	95
25	CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlaa112.	2.1	18
26	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. <i>Thorax</i> , 2021, 76, 920-929.	5.6	60
27	Interplay among Different Fosfomicin Resistance Mechanisms in <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	7
28	Making treatment decisions in a void of information. <i>Nature Medicine</i> , 2021, 27, 575-575.	30.7	0
29	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. <i>Antibiotics</i> , 2021, 10, 348.	3.7	3
30	Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 1122-1129.	1.8	72
31	Efficacy of Fosfomicin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Clinical Strains. <i>Frontiers in Medicine</i> , 2021, 8, 615540.	2.6	5
32	A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1746-1753.	6.0	5
33	Incidence and predictive biomarkers of <i>Clostridioides difficile</i> infection in hospitalized patients receiving broad-spectrum antibiotics. <i>Nature Communications</i> , 2021, 12, 2240.	12.8	21
34	Activity of Fosfomicin and Amikacin against Fosfomicin-Heteroresistant <i>Escherichia coli</i> Strains in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	3
35	Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab250.	0.9	11
36	Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2172-2181.	3.0	19

#	ARTICLE	IF	CITATIONS
37	Phenotypic and molecular characterizations of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates collected within the EURECA study. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106345.	2.5	21
38	Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 25, 5-7.	2.2	27
39	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 783-792.	9.1	62
40	Clinical characteristics and outcome of bacteraemia caused by <i>Enterobacter cloacae</i> and <i>Klebsiella aerogenes</i> : more similarities than differences. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 25, 351-358.	2.2	16
41	Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106352.	2.5	9
42	Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing Enterobacterales in kidney transplant recipients: a propensity score and DOOR-based analysis.. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0110221.	3.2	2
43	Household acquisition and transmission of extended-spectrum β -lactamase (ESBL) -producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1322-1329.	6.0	14
44	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. <i>Viral Immunology</i> , 2021, 34, 639-645.	1.3	13
45	Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant <i>Enterobacterales</i> (ASTART $\%$): protocol for a randomised, pragmatic trial. <i>BMJ Open</i> , 2021, 11, e049481.	1.9	6
46	Unneeded antibiotics for acute respiratory infections in primary care: stop as early as possible. <i>Clinical Microbiology and Infection</i> , 2021, , .	6.0	1
47	Interplay between IncF plasmids and topoisomerase mutations conferring quinolone resistance in the <i>Escherichia coli</i> ST131 clone: stability and resistance evolution. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, , 1.	2.9	0
48	Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. <i>Scientific Reports</i> , 2021, 11, 23380.	3.3	39
49	Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 358-365.	6.0	30
50	A prospective, multicenter case control study of risk factors for acquisition and mortality in <i>Enterobacter</i> species bacteremia. <i>Journal of Infection</i> , 2020, 80, 174-181.	3.3	15
51	Weighting the impact of virulence on the outcome of <i>Pseudomonas aeruginosa</i> bloodstream infections. <i>Clinical Microbiology and Infection</i> , 2020, 26, 351-357.	6.0	11
52	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for <i>Pseudomonas aeruginosa</i> Bloodstream Infection: A Multisite Retrospective Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2270-2280.	5.8	24
53	Guidance on reporting multivariable regression models in CMI. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1-2.	6.0	21
54	Reply to Woerther et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 1129-1130.	5.8	0

#	ARTICLE	IF	CITATIONS
55	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , 2020, 20, 1629-1641.	4.7	17
56	How to limit bias in quasiexperimental studies. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 45-46.	0.3	0
57	Risk factors for mortality among patients with <i>Pseudomonas aeruginosa</i> bacteraemia: a retrospective multicentre study. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105847.	2.5	33
58	Cómo limitar los sesgos en estudios cuasiexperimentales. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 45-46.	0.5	0
59	Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30-day mortality in a multicentre prospective cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3056-3061.	3.0	12
60	Therapy of <i>Staphylococcus aureus</i> bacteremia: Evidences and challenges. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 489-497.	0.5	8
61	Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. <i>BMJ Open</i> , 2020, 10, e039951.	1.9	14
62	Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1525-1536.	6.0	249
63	Outcome of community-onset ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bacteraemia and urinary tract infection: a population-based cohort study in Denmark. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3656-3664.	3.0	17
64	Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, ii2-ii19.	3.0	9
65	Impact of KPC Production and High-Level Meropenem Resistance on All-Cause Mortality of Ventilator-Associated Pneumonia in Association with <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	11
66	Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol. <i>BMJ Open</i> , 2020, 10, e030608.	1.9	7
67	Submissions and publications in corona times. <i>Clinical Microbiology and Infection</i> , 2020, 26, 803-804.	6.0	8
68	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1837-1844.	2.9	11
69	Contribution of hypermutation to fosfomycin heteroresistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2066-2075.	3.0	6
70	Reply to "CMV merits further evolutionary and biological view". <i>American Journal of Transplantation</i> , 2020, 20, 1467-1468.	4.7	1
71	A comparative study between real-time PCR and loop-mediated isothermal amplification to detect carbapenemase and/or ESBL genes in Enterobacteriaceae directly from bronchoalveolar lavage fluid samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1453-1457.	3.0	9
72	Reporting methods of observational cohort studies in CMI. <i>Clinical Microbiology and Infection</i> , 2020, 26, 395-398.	6.0	9

#	ARTICLE	IF	CITATIONS
73	Evaluation of a Loop-Mediated Isothermal Amplification Assay to Detect Carbapenemases Directly From Bronchoalveolar Lavage Fluid Spiked With <i>Acinetobacter</i> spp.. <i>Frontiers in Microbiology</i> , 2020, 11, 597684.	3.5	2
74	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	33
75	Therapy of <i>Staphylococcus aureus</i> bacteremia: Evidences and challenges. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 489-497.	0.3	0
76	Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project. <i>BMJ Open</i> , 2020, 10, e035460.	1.9	0
77	Predictive value of the kinetics of procalcitonin and C-reactive protein for early clinical stability in patients with bloodstream infections due to Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 63-68.	1.8	11
78	Development and validation of baseline, perioperative and at-discharge predictive models for postsurgical prosthetic joint infection. <i>Clinical Microbiology and Infection</i> , 2019, 25, 196-202.	6.0	6
79	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteraemia cohort: the prognostic significance of colistin resistance. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 442-448.	2.5	11
80	Impact of Initial Antifungal Therapy on the Outcome of Patients With Candidemia and Septic Shock Admitted to Medical Wards: A Propensity Score-Adjusted Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz251.	0.9	11
81	“Being a parent at ECCMID 2019” – ESCMID’s reply. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1161.	6.0	0
82	Prognosis of urinary tract infection caused by KPC-producing <i>Klebsiella pneumoniae</i> : The impact of inappropriate empirical treatment. <i>Journal of Infection</i> , 2019, 79, 245-252.	3.3	12
83	The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. <i>Clinical Microbiology and Infection</i> , 2019, 25, 555-561.	6.0	51
84	Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality in <i>Staphylococcus aureus</i> bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1101-1107.	3.0	18
85	Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: Results of an online survey. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 478-486.	2.5	31
86	Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 932-942.	6.0	74
87	Does Online Search Behavior Coincide with <i>Candida auris</i> Cases? An Exploratory Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 44.	3.5	3
88	Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β -lactamase (ESBL) or AmpC β -lactamase: A propensity score study. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 189-196.	2.5	15
89	Rates, predictors and mortality of community-onset bloodstream infections due to <i>Pseudomonas aeruginosa</i> : systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 964-970.	6.0	21
90	A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance. <i>Nature Microbiology</i> , 2019, 4, 1160-1172.	13.3	58

#	ARTICLE	IF	CITATIONS
91	Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 612.	7.4	20
92	ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. <i>Clinical Microbiology and Infection</i> , 2019, 25, 807-817.	6.0	114
93	<p>The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 329-343.	2.7	21
94	Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe. <i>BMJ Open</i> , 2019, 9, e027683.	1.9	25
95	Opportunities for antibiotic optimisation and outcome improvement in patients with negative blood cultures: study protocol for a cluster-randomised crossover trial, the NO-BACT study. <i>BMJ Open</i> , 2019, 9, e030062.	1.9	1
96	Combined Use of the Ab105-2Ï†CI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant <i>Acinetobacter baumannii</i> . <i>Microorganisms</i> , 2019, 7, 556.	3.6	33
97	Impact of infectious diseases consultation on the outcome of patients with bacteraemia. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611989357.	1.8	6
98	Rhodomyrtone decreases <i>Staphylococcus aureus</i> SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles. <i>Microbial Pathogenesis</i> , 2019, 128, 112-118.	2.9	11
99	ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus. <i>Clinical Microbiology and Infection</i> , 2019, 25, 13-19.	6.0	42
100	Rationalizing antimicrobial therapy in the ICU: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 172-189.	8.2	155
101	Extended Infusion of Î²-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1731-1739.	5.8	29
102	ESCMID white paper: a guide on ESCMID guidance documents. <i>Clinical Microbiology and Infection</i> , 2019, 25, 155-162.	6.0	1
103	Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. <i>Clinical Infectious Diseases</i> , 2019, 69, 956-962.	5.8	18
104	Vagino-rectal colonization and maternalâ€œneonatal transmission of Enterobacteriaceae producing extended-spectrum Î²-lactamases or carbapenemases: a cross-sectional study. <i>Journal of Hospital Infection</i> , 2019, 101, 167-174.	2.9	21
105	La formaciÃ³n de grado en enfermedades infecciosas, resistencia y uso de antibiÃ³ticos desde la perspectiva de los estudiantes de Medicina. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 25-30.	0.5	11
106	A step forward in the definition of antimicrobial stewardship indicators: Better measurements, better work. <i>Farmacia Hospitalaria</i> , 2019, 43, 77-78.	0.6	2
107	Prosthetic Valve <i>Candida</i> spp. Endocarditis: New Insights Into Long-term Prognosisâ€œThe ESCAPE Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 825-832.	5.8	40
108	In Replyâ€œStatin Use Associated With a Decreased Risk of Community-Acquired <i>Staphylococcus aureus</i> Bacteremia. <i>Mayo Clinic Proceedings</i> , 2018, 93, 542.	3.0	0

#	ARTICLE	IF	CITATIONS
109	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.8	49
110	Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2018, 24, 1177-1183.	6.0	18
111	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1070-1076.	6.0	58
112	Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	13.6	486
113	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018, 44, 189-196.	8.2	101
114	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 318-327.	9.1	3,672
115	Risks of Infection and Mortality Among Patients Colonized With <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : Validation of Scores and Proposal for Management. <i>Clinical Infectious Diseases</i> , 2018, 66, 1204-1210.	5.8	81
116	The impact of initial antibiotic treatment failure: Real-world insights in healthcare-associated or nosocomial pneumonia. <i>Journal of Infection</i> , 2018, 77, 9-17.	3.3	18
117	Evaluation of the impact of a nationwide massive online open course on the appropriate use of antimicrobials. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2231-2235.	3.0	10
118	The role of tigecycline in the management of <i>Clostridium difficile</i> infection: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 180-184.	6.0	16
119	The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information. <i>Clinical Microbiology and Infection</i> , 2018, 24, 105-109.	6.0	40
120	ESCMID-an international Europe-based society committed to fostering cross-border collaboration and education to improve patient care. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1-2.	6.0	40
121	Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans. <i>Clinical Microbiology and Infection</i> , 2018, 24, 577-590.	6.0	85
122	Direct bacterial identification from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 484-492.	0.5	21
123	Prevalence of Aminoglycoside-Modifying Enzymes in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Producing Extended Spectrum β -Lactamases Collected in Two Multicenter Studies in Spain. <i>Microbial Drug Resistance</i> , 2018, 24, 367-376.	2.0	26
124	Prevalence and transmission dynamics of <i>Escherichia coli</i> ST131 among contacts of infected community and hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 618-623.	6.0	19
125	Clinical predictors of methicillin-resistant <i>Staphylococcus aureus</i> in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 51-56.	2.9	16
126	Surveillance for control of antimicrobial resistance. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e99-e106.	9.1	235

#	ARTICLE	IF	CITATIONS
127	The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection. <i>Journal of Infection</i> , 2018, 76, 121-131.	3.3	18
128	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 546.e1-546.e8.	6.0	67
129	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. <i>Germs</i> , 2018, 8, 109-112.	1.3	7
130	Duration of Colonization by Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Healthy Newborns and Associated Risk Factors: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy312.	0.9	5
131	Intestinal colonization due to <i>Escherichia coli</i> ST131: risk factors and prevalence. <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 135.	4.1	18
132	Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by <i>A. baumannii</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 3105.	3.5	14
133	How are trainees in clinical microbiology and infectious diseases supervised in Europe? An international cross-sectional questionnaire survey by the Trainee Association of ESCMID. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2381-2387.	2.9	6
134	Incidence and Risk Factors for Acquisition of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Newborns in Seville, Spain: A Prospective Cohort Study. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 835-841.	2.5	5
135	Unsolicited consultation by infectious diseases specialist improves outcomes in patients with bloodstream infection: A prospective cohort study. <i>Journal of Infection</i> , 2018, 77, 503-508.	3.3	6
136	Survival following <i>Staphylococcus aureus</i> bloodstream infection: A prospective multinational cohort study assessing the impact of place of care. <i>Journal of Infection</i> , 2018, 77, 516-525.	3.3	48
137	Risk Factors for Treatment Failure and Mortality among Hospitalised Patients with Complicated Urinary Tract Infection: A Multicentre Retrospective Cohort Study, RESCUING Study Group. <i>Clinical Infectious Diseases</i> , 2018, 68, 29-36.	5.8	40
138	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 577-585.	2.5	36
139	Social media posts and online search behaviour as early-warning system for MRSA outbreaks. <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 69.	4.1	17
140	Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of <i>Klebsiella pneumoniae</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 912.	3.5	16
141	Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study. <i>Journal of Hepatology</i> , 2018, 68, S44-S45.	3.7	2
142	Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vi50-vi58.	3.0	89
143	Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vi30-vi39.	3.0	43
144	Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. <i>BMJ Open</i> , 2018, 8, e020251.	1.9	34

#	ARTICLE	IF	CITATIONS
145	Analysis of quality antimicrobial agent use in the emergency department of a tertiary care hospital. <i>Emergencias</i> , 2018, 30, 297-302.	0.6	15
146	Gender differences in the outcome of community-acquired <i>Staphylococcus aureus</i> bacteraemia: a historical population-based cohort study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 27-32.	6.0	29
147	Molecular insights into fosfomycin resistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw573.	3.0	29
148	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum β -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	3.0	46
149	Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. <i>Clinical Microbiology and Infection</i> , 2017, 23, 325-331.	6.0	38
150	Epidemiology and control measures of outbreaks due to Antibiotic-Resistant organisms in Europe (EMBARGO): a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e013634.	1.9	9
151	Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. <i>Clinical Microbiology and Infection</i> , 2017, 23, 672.e1-672.e11.	6.0	25
152	MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw562.	3.0	17
153	The Use of Noncarbapenem β -Lactams for the Treatment of Extended-Spectrum β -Lactamase Infections. <i>Clinical Infectious Diseases</i> , 2017, 64, 972-980.	5.8	145
154	European prospective cohort study on <i>Enterobacteriaceae</i> showing Resistance to Carbapenems (EURECA): a protocol of a European multicentre observational study. <i>BMJ Open</i> , 2017, 7, e015365.	1.9	22
155	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	9.1	367
156	Surveillance Systems from Public Health Institutions and Scientific Societies for Antimicrobial Resistance and Healthcare-Associated Infections in Europe (SUSPIRE): protocol for a systematic review. <i>BMJ Open</i> , 2017, 7, e014538.	1.9	4
157	Overproduction of outer membrane protein A (OmpA) by <i>Acinetobacter baumannii</i> is a risk factor for nosocomial pneumonia, bacteremia and mortality increase. <i>Journal of Infectious Diseases</i> , 2017, 215, jix010.	4.0	42
158	Clinical efficacy of β -lactam/ β -lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β -lactamase-producing <i>Enterobacteriaceae</i> in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). <i>BMJ Open</i> , 2017, 7, e013268.	1.9	8
159	Patient engagement with surgical site infection prevention: an expert panel perspective. <i>Antimicrobial Resistance and Infection Control</i> , 2017, 6, 45.	4.1	55
160	Mortality Associated with Bacteremia Due to Colistin-Resistant <i>Klebsiella pneumoniae</i> with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	59
161	High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2102-2109.	3.0	11
162	Bacteraemia due to non-ESBL-producing <i>Escherichia coli</i> O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 498-502.	2.5	15

#	ARTICLE	IF	CITATIONS
163	Intravenous fosfomicin “back to the future. Systematic review and meta-analysis of the clinical literature. <i>Clinical Microbiology and Infection</i> , 2017, 23, 363-372.	6.0	119
164	Efficacy of β -Lactam/ β -Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	41
165	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae “ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1020-1021.	9.1	10
166	Epidemiology and prognosis of candidaemia in elderly patients. <i>Mycoses</i> , 2017, 60, 808-817.	4.0	20
167	How should we best treat patients with bloodstream infections?. <i>Future Microbiology</i> , 2017, 12, 927-930.	2.0	9
168	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	2.5	8
169	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. <i>Surgical Infections</i> , 2017, 18, 846-853.	1.4	31
170	Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1469-1478.	3.0	20
171	Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to <i>Enterobacteriaceae</i> (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial. <i>BMJ Open</i> , 2017, 7, e015439.	1.9	7
172	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. <i>Clinical Microbiology and Infection</i> , 2017, 23, 533-541.	6.0	58
173	Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. <i>Clinical Microbiology and Infection</i> , 2017, 23, 49.e1-49.e8.	6.0	41
174	Amoxicillin dosing recommendations are very different in European countries: a cross-sectional survey. <i>Clinical Microbiology and Infection</i> , 2017, 23, 414-415.	6.0	18
175	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	5.8	43
176	Response to Bile Salts in Clinical Strains of <i>Acinetobacter baumannii</i> Lacking the AdeABC Efflux Pump: Virulence Associated with Quorum Sensing. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 143.	3.9	40
177	AMS in an Era of Multidrug-Resistant Bacteria. , 2017, , 219-231.		0
178	Antimicrobial Stewardship in Spain. , 2017, , 317-319.		0
179	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship “results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , 2017, 12, 34.	5.0	47
180	Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. <i>Antimicrobial Resistance and Infection Control</i> , 2017, 6, 113.	4.1	186

#	ARTICLE	IF	CITATIONS
181	Quorum sensing network in clinical strains of <i>A. baumannii</i> : AidA is a new quorum quenching enzyme. PLoS ONE, 2017, 12, e0174454.	2.5	54
182	Introduction by Jesús Rodríguez-Baño, 2017, , xix.		0
183	Staffing for infectious diseases, clinical microbiology and infection control in hospitals in 2015: results of an ESCMID member survey. Clinical Microbiology and Infection, 2016, 22, 812.e9-812.e17.	6.0	39
184	Modelling the epidemiology of <i>Escherichia coli</i> ST131 and the impact of interventions on the community and healthcare centres. Epidemiology and Infection, 2016, 144, 1974-1982.	2.1	11
185	Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clinical Microbiology and Infection, 2016, 22, 733.e1-733.e8.	6.0	34
186	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
187	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
188	Deciphering the Resistome of the Widespread <i>Pseudomonas aeruginosa</i> Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	3.2	99
189	Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing <i>Klebsiella pneumoniae</i> . Journal of Antimicrobial Chemotherapy, 2016, 71, 3242-3249.	3.0	36
190	CTX-M-15- <i>H30Rx</i> -ST131 subclone is one of the main causes of healthcare-associated ESBL-producing <i>Escherichia coli</i> bacteraemia of urinary origin in Spain. Journal of Antimicrobial Chemotherapy, 2016, 71, 2125-2130.	3.0	46
191	Risk factors, clinical presentation and prognosis of mixed candidaemia: a population-based surveillance in Spain. Mycoses, 2016, 59, 636-643.	4.0	8
192	Should we take into account ESBLs in empirical antibiotic treatment?. Intensive Care Medicine, 2016, 42, 2059-2062.	8.2	7
193	Genomic Evolution of Two <i>Acinetobacter baumannii</i> Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010). Genome Announcements, 2016, 4, .	0.8	6
194	Clinical characteristics, treatment and outcomes of MRSA bacteraemia in the elderly. Journal of Infection, 2016, 72, 309-316.	3.3	11
195	<i>Acinetobacter baumannii</i> in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality. Enfermedades Infecciosas Y Microbiología Clínica, 2016, 34, 551-558.	0.5	23
196	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
197	<i>Escherichia coli</i> : an old friend with new tidings. FEMS Microbiology Reviews, 2016, 40, 437-463.	8.6	225
198	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. Journal of Antimicrobial Chemotherapy, 2016, 71, 521-530.	3.0	21

#	ARTICLE	IF	CITATIONS
199	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. <i>Journal of Infection</i> , 2016, 72, 152-160.	3.3	73
200	Current Epidemiology and Outcome of Infective Endocarditis. <i>Medicine (United States)</i> , 2015, 94, e1816.	1.0	129
201	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) catheter-related bacteraemia in haemodialysis patients. <i>BMC Infectious Diseases</i> , 2015, 15, 484.	2.9	7
202	Letter by Almendro-Delia et al Regarding Article, "Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis: A Prospective Study From the International Collaboration on Endocarditis". <i>Circulation</i> , 2015, 132, e183.	1.6	0
203	Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β -lactams: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1751-1758.	2.9	6
204	The global threat of antimicrobial resistance: science for intervention. <i>New Microbes and New Infections</i> , 2015, 6, 22-29.	1.6	811
205	Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2652-2660.	3.0	19
206	Effects of isolation on patients and staff. <i>American Journal of Infection Control</i> , 2015, 43, 397-399.	2.3	29
207	Early oral switch therapy in low-risk <i>Staphylococcus aureus</i> bloodstream infection (SABATO): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 450.	1.6	42
208	Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: Impact of antimicrobial resistance in a large hospitalised cohort. <i>Journal of Infection</i> , 2015, 70, 247-254.	3.3	17
209	World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance. <i>Medicina Intensiva</i> , 2015, 39, 34-39.	0.7	14
210	Prolonged treatment with large doses of fosfomicin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant <i>Staphylococcus epidermidis</i> and IMP-8 metallo- β -lactamase-producing <i>Klebsiella oxytoca</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 313-315.	3.0	14
211	Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 337.e1-337.e21.	0.5	29
212	Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 338-341.	0.5	23
213	Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 905-913.	3.0	91
214	Uncoupling between core genome and virulome in extraintestinal pathogenic <i>Escherichia coli</i> . <i>Canadian Journal of Microbiology</i> , 2015, 61, 647-652.	1.7	3
215	Daptomycin plus fosfomicin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. <i>BMJ Open</i> , 2015, 5, e006723-e006723.	1.9	38
216	Fosfomicin Versus Meropenem In Bacteremic Urinary Tract Infections Caused By Extended-Spectrum β -lactamase Producing <i>Escherichia coli</i> (Esbl-Ec): Forest Study. <i>Clinical Therapeutics</i> , 2015, 37, e34-e35.	2.5	1

#	ARTICLE	IF	CITATIONS
217	Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. <i>Journal of Infection</i> , 2015, 71, 385-394.	3.3	39
218	The Times They Are a-Changin': Carbapenems for Extended-Spectrum- β -Lactamase-Producing Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5095-5096.	3.2	11
219	Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain: Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2916-2918.	3.0	11
220	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5602-5610.	3.2	87
221	In reply "What Is the Optimal Timing for Surgical Treatment of Infective Endocarditis?. <i>Mayo Clinic Proceedings</i> , 2015, 90, 415-416.	3.0	1
222	Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. <i>Clinical Microbiology and Infection</i> , 2015, 21, 491.e1-491.e10.	6.0	57
223	Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β -lactamase-producing <i>Escherichia coli</i> (FOREST): study protocol for an investigator-driven randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e007363-e007363.	1.9	61
224	Combatting resistance in intensive care: the multimodal approach of the Spanish ICU "Zero Resistance" program. <i>Critical Care</i> , 2015, 19, 114.	5.8	53
225	Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to <i>Staphylococcus aureus</i> . A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 626-632.	0.5	34
226	Diagnosis and treatment of bacteremia and endocarditis due to <i>Staphylococcus aureus</i> . A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 625.e1-625.e23.	0.5	32
227	Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High <i>In Vitro</i> Susceptibility to Colistin and Meropenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3406-3412.	3.2	130
228	Reduced susceptibility to biocides in <i>Acinetobacter baumannii</i> : association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3222-3229.	3.0	65
229	Left-sided infective endocarditis in patients with liver cirrhosis. <i>Journal of Infection</i> , 2015, 71, 627-641.	3.3	14
230	Minimum requirements in infection control. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1072-1076.	6.0	20
231	Influence of Virulence Genotype and Resistance Profile in the Mortality of <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2015, 60, 539-548.	5.8	153
232	European survey on principles of prudent antibiotic prescribing teaching in undergraduate students. <i>Clinical Microbiology and Infection</i> , 2015, 21, 354-361.	6.0	44
233	Lessons from an outbreak of metallo- β -lactamase-producing <i>Klebsiella oxytoca</i> in an intensive care unit: the importance of time at risk and combination therapy. <i>Journal of Hospital Infection</i> , 2015, 89, 123-131.	2.9	23
234	Reply to Fries et al and Valentin et al. <i>Clinical Infectious Diseases</i> , 2014, 58, 600-601.	5.8	0

#	ARTICLE	IF	CITATIONS
235	Global dissemination of a multidrug resistant <i>Escherichia coli</i> clone. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5694-5699.	7.1	498
236	Treatment of infections caused by carbapenemase-producing Enterobacteriaceae. Enfermedades Infecciosas Y Microbiología Clínica, 2014, 32, 49-55.	0.5	9
237	Carbapenemase-producing Enterobacteriaceae: The end of the antibiotic era?. Enfermedades Infecciosas Y Microbiología Clínica, 2014, 32, 1-3.	0.5	8
238	Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies. Future Microbiology, 2014, 9, 757-771.	2.0	10
239	Lack of association between genotypes and haematogenous seeding infections in a large cohort of patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia from 21 Spanish hospitals. Clinical Microbiology and Infection, 2014, 20, 361-367.	6.0	14
240	Characterisation of the first ongoing outbreak due to KPC-3-producing <i>Klebsiella pneumoniae</i> (ST512) in Spain. International Journal of Antimicrobial Agents, 2014, 44, 538-540.	2.5	46
241	<i>Staphylococcus aureus</i> bloodstream infection: A pooled analysis of five prospective, observational studies. Journal of Infection, 2014, 68, 242-251.	3.3	207
242	ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clinical Microbiology and Infection, 2014, 20, 1-55.	6.0	640
243	Epidemiology and predictive factors for early and late mortality in <i>Candida</i> bloodstream infections: a population-based surveillance in Spain. Clinical Microbiology and Infection, 2014, 20, O245-O254.	6.0	241
244	Characterization of plasmids carrying the bla _{OXA-24/40} carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system*. Journal of Antimicrobial Chemotherapy, 2014, 69, 2629-2633.	3.0	43
245	Dalbavancin or Oritavancin for Skin Infections. New England Journal of Medicine, 2014, 371, 1160-1163.	27.0	10
246	Initial Use of Echinocandins Does Not Negatively Influence Outcome in <i>Candida parapsilosis</i> Bloodstream Infection: A Propensity Score Analysis. Clinical Infectious Diseases, 2014, 58, 1413-1421.	5.8	104
247	Influence of Early Surgical Treatment on the Prognosis of Left-Sided Infective Endocarditis: A Multicenter Cohort Study. Mayo Clinic Proceedings, 2014, 89, 1397-1405.	3.0	33
248	Predictors of early mortality in very elderly patients with bacteremia: a prospective multicenter cohort. International Journal of Infectious Diseases, 2014, 26, 83-87.	3.3	25
249	Monotherapy versus combination therapy for sepsis due to multidrug-resistant <i>Acinetobacter baumannii</i> : analysis of a multicentre prospective cohort—authors' response. Journal of Antimicrobial Chemotherapy, 2014, 69, 3167-3168.	3.0	5
250	Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2014, 69, 3203-3215.	3.0	76
251	Within-lineage variability of ST131 <i>Escherichia coli</i> isolates from humans and companion animals in the south of Europe. Journal of Antimicrobial Chemotherapy, 2014, 69, 271-273.	3.0	17
252	Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant <i>Staphylococcus aureus</i> persistent bacteraemia treated with daptomycin. Journal of Antimicrobial Chemotherapy, 2014, 69, 568-571.	3.0	56

#	ARTICLE	IF	CITATIONS
253	Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 809-814.	3.0	52
254	Are hip hemiarthroplasty and total hip arthroplasty infections different entities? The importance of hip fractures. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 1439-1448.	2.9	26
255	Monotherapy versus combination therapy for sepsis due to multidrug-resistant <i>Acinetobacter baumannii</i> : analysis of a multicentre prospective cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3119-3126.	3.0	81
256	Epidemiologic and Clinical Impact of <i>Acinetobacter baumannii</i> Colonization and Infection. <i>Medicine (United States)</i> , 2014, 93, 202-210.	1.0	53
257	Scientific evidence and research in antimicrobial stewardship. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 56-61.	0.5	4
258	Wastewater drainage system as an occult reservoir in a protracted clonal outbreak due to metallo- β -lactamase-producing <i>Klebsiella oxytoca</i> . <i>Clinical Microbiology and Infection</i> , 2013, 19, E490-E498.	6.0	104
259	Outcome of bacteraemia due to extended-spectrum β -lactamase-producing <i>Escherichia coli</i> : Impact of microbiological determinants. <i>Journal of Infection</i> , 2013, 67, 27-34.	3.3	22
260	Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. <i>Clinical Microbiology and Infection</i> , 2013, 19, 962-968.	6.0	104
261	Contribution of Efflux Pumps, Porins, and β -Lactamases to Multidrug Resistance in Clinical Isolates of <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5247-5257.	3.2	170
262	Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by <i>Escherichia coli</i> with or without the GyrA mutation Ser83Leu. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1609-1615.	3.0	29
263	Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in <i>Pseudomonas aeruginosa</i> Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 208-216.	5.8	135
264	Reappraisal of the outcome of healthcare-associated and community-acquired bacteraemia: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 344.	2.9	12
265	Prevalence and molecular epidemiology of acquired AmpC β -lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 253-259.	2.9	91
266	Antimicrobial stewardship programs: A public health priority in Spain. The SEIMC-REIPI initiative. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 1-2.	0.5	5
267	<i>Escherichia coli</i> O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 385-388.	0.5	22
268	Knowledge and perceptions of junior and senior Spanish resident doctors about antibiotic use and resistance: Results of a multicenter survey. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 199-204.	0.5	57
269	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. <i>Journal of Infection</i> , 2013, 67, 185-193.	3.3	25
270	Successful multifaceted intervention aimed to reduce short peripheral venous catheter-related adverse events: A quasiexperimental cohort study. <i>American Journal of Infection Control</i> , 2013, 41, 520-526.	2.3	44

#	ARTICLE	IF	CITATIONS
271	Impact of an Evidence-Based Bundle Intervention in the Quality-of-Care Management and Outcome of Staphylococcus aureus Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 57, 1225-1233.	5.8	192
272	Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum- β -Lactamase-Producing Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3402-3404.	3.2	90
273	Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1423-1430.	3.0	44
274	Four Main Virotypes among Extended-Spectrum- β -Lactamase-Producing Isolates of Escherichia coli O25b:H4-B2-ST131: Bacterial, Epidemiological, and Clinical Characteristics. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3358-3367.	3.9	76
275	Clinical management of infections caused by multidrug-resistant <i>Enterobacteriaceae</i> . <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 49-69.	1.8	50
276	Editorial. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 3-3.	1.8	2
277	First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 589-591.	3.2	23
278	Prevalence of and Risk Factors for Biliary Carriage of Bacteria Showing Worrisome and Unexpected Resistance Traits. <i>Journal of Clinical Microbiology</i> , 2013, 51, 518-521.	3.9	18
279	Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum- β -lactamase-producing Klebsiella pneumoniae. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 68-73.	3.0	106
280	Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β -Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2109-2113.	3.2	51
281	Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. <i>Clinical Microbiology and Infection</i> , 2013, 19, 1049-1057.	6.0	67
282	Epidemiological and Clinical Complexity of Amoxicillin-Clavulanate-Resistant Escherichia coli. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2414-2417.	3.9	13
283	Effect of Statin Therapy in the Outcome of Bloodstream Infections Due to Staphylococcus aureus: A Prospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e82958.	2.5	28
284	Prognosis of 2009 A(H1N1) Influenza in Hospitalized Pregnant Women in a Context of Early Diagnosis and Antiviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 719-728.	1.0	8
285	Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1265-1272.	3.2	123
286	Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3576-3581.	3.2	49
287	Treatment of Sepsis-Related Organ Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1205.	7.4	0
288	Impact of Inadequate Empirical Therapy on the Mortality of Patients with Bloodstream Infections: a Propensity Score-Based Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 472-478.	3.2	182

#	ARTICLE	IF	CITATIONS
289	Daptomycin or Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> with a Vancomycin Minimum Inhibitory Concentration >1 µg/L. <i>Clinical Infectious Diseases</i> , 2012, 54, 1375-1376.	5.8	2
290	β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing <i>Escherichia coli</i> : A Post Hoc Analysis of Prospective Cohorts. <i>Clinical Infectious Diseases</i> , 2012, 54, 167-174.	5.8	329
291	Increased raw poultry meat colonization by extended spectrum beta-lactamase-producing <i>Escherichia coli</i> in the south of Spain. <i>International Journal of Food Microbiology</i> , 2012, 159, 69-73.	4.7	79
292	Pregnancy, obesity and other risk factors for complications in influenza A(H1N1) pdm09 infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012, 30, 32-37.	0.5	10
293	Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2012, 18, 894-900.	6.0	36
294	Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season. <i>Clinical Microbiology and Infection</i> , 2012, 18, E55-E62.	6.0	44
295	Assessing the influence of risk factors on rates and dynamics of peripheral vein phlebitis: An observational cohort study. <i>Medicina Clínica</i> , 2012, 139, 185-191.	0.6	48
296	Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study. <i>BMC Research Notes</i> , 2012, 5, 578.	1.4	2
297	Prevalence of plasmid-mediated quinolone resistance determinants qnr and aac(6)-Ib-cr in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> producing extended-spectrum β-lactamases in Spain. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 431-434.	2.5	107
298	Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 472-477.	2.5	23
299	Epidemiological and clinical features associated with colonisation/infection by <i>Acinetobacter baumannii</i> with phenotypic heterogeneous resistance to carbapenems. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 235-238.	2.5	14
300	Clinical and molecular epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> causing bacteraemia in Southern Spain. <i>Journal of Hospital Infection</i> , 2012, 81, 257-263.	2.9	15
301	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 547-556.	2.9	31
302	Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. <i>Journal of Infection</i> , 2012, 64, 176-183.	3.3	45
303	Virulence Profiles of Bacteremic Extended-Spectrum β-Lactamase-Producing <i>Escherichia coli</i> : Association with Epidemiological and Clinical Features. <i>PLoS ONE</i> , 2012, 7, e44238.	2.5	35
304	“The 3/3 Strategy”: A Successful Multifaceted Hospital Wide Hand Hygiene Intervention Based on WHO and Continuous Quality Improvement Methodology. <i>PLoS ONE</i> , 2012, 7, e47200.	2.5	39
305	<i>Klebsiella pneumoniae</i> Strains Producing Extended-Spectrum β-Lactamases in Spain: Microbiological and Clinical Features. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1134-1136.	3.9	25
306	Characterisation of clinical and food animal <i>Escherichia coli</i> isolates producing CTX-M-15 extended-spectrum β-lactamase belonging to ST410 phylogroup A. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 365-367.	2.5	44

#	ARTICLE	IF	CITATIONS
307	Control measures for <i>Acinetobacter baumannii</i> : a survey of Spanish hospitals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 36-38.	0.5	8
308	New trends in infective endocarditis. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 22-35.	0.5	4
309	Pneumonia Complicating Pandemic (H1N1) 2009. <i>Medicine (United States)</i> , 2011, 90, 328-336.	1.0	32
310	Timing of Oseltamivir Administration and Outcomes in Hospitalized Adults With Pandemic 2009 Influenza A(H1N1) Virus Infection. <i>Chest</i> , 2011, 140, 1025-1032.	0.8	57
311	Perspectives from Spanish infectious diseases professionals on 2009 A (H1N1) influenza: the third half. <i>Clinical Microbiology and Infection</i> , 2011, 17, 845-850.	6.0	8
312	Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. <i>Clinical Microbiology and Infection</i> , 2011, 17, 738-746.	6.0	93
313	Biofilm formation at the solid-liquid and air-liquid interfaces by <i>Acinetobacter</i> species. <i>BMC Research Notes</i> , 2011, 4, 5.	1.4	84
314	Assessment of the presence of extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> in eggshells and ready-to-eat products. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 1045-1047.	2.9	21
315	Evaluation of two different control charts (I and U) in the study of multiresistant bacteria contact precautions dynamics in a non-endemicity hospital setting. <i>BMC Proceedings</i> , 2011, 5, .	1.6	0
316	Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. <i>Journal of Infection</i> , 2011, 62, 193-199.	3.3	64
317	National survey of <i>Escherichia coli</i> causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2011-2021.	3.0	117
318	Similarities between the genetic environments of blaCTX-M-15 in <i>Escherichia coli</i> from clinical and food samples from Spain and overseas travellers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2177-2177.	3.0	3
319	A comprehensive surveillance, control and management programme for <i>Clostridium difficile</i> infection. <i>Journal of Hospital Infection</i> , 2010, 74, 91-93.	2.9	4
320	Prognostic factors in left-sided endocarditis: results from the andalusian multicenter cohort. <i>BMC Infectious Diseases</i> , 2010, 10, 17.	2.9	70
321	Comparative assessment of inoculum effects on the antimicrobial activity of amoxicillin-clavulanate and piperacillin-tazobactam with extended-spectrum β -lactamase-producing and extended-spectrum β -lactamase-non-producing <i>Escherichia coli</i> isolates.. <i>Clinical Microbiology and Infection</i> , 2010, 16, 132-136.	6.0	71
322	Extended-spectrum and CMY-type β -lactamase-producing <i>Escherichia coli</i> in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. <i>Clinical Microbiology and Infection</i> , 2010, 16, 33-38.	6.0	133
323	Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1408-1413.	6.0	87
324	Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 1726-1731.	3.9	144

#	ARTICLE	IF	CITATIONS
325	Reply to Tarchini. <i>Clinical Infectious Diseases</i> , 2010, 51, 120-121.	5.8	38
326	Clinical Features of Infections and Colonization by <i>Acinetobacter</i> Genospecies 3. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4623-4626.	3.9	12
327	Isolation of multidrug-resistant <i>Klebsiella oxytoca</i> carrying bla _{IMP-8} , associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1071-1073.	3.0	16
328	Diversity of <i>Escherichia coli</i> Strains Producing Extended-Spectrum β -Lactamases in Spain: Second Nationwide Study. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2840-2845.	3.9	86
329	Community-Onset Bacteremia Due to Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> : Risk Factors and Prognosis. <i>Clinical Infectious Diseases</i> , 2010, 50, 40-48.	5.8	294
330	Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. <i>Aids</i> , 2010, 24, 2461-2467.	2.2	38
331	Long-Term Control of Endemic Hospital-Wide Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA): The Impact of Targeted Active Surveillance for MRSA in Patients and Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 786-795.	1.8	31
332	A dynamic in vitro model for evaluating antimicrobial activity against bacterial biofilms using a new device and clinical-used catheters. <i>Journal of Microbiological Methods</i> , 2010, 83, 307-311.	1.6	8
333	Prudent use of antimicrobials: Have we done the best we can? The SEIMC and REIPI statement. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010, 28, 485-486.	0.5	6
334	Prudent use of antibacterial agents: are we entering in an era of infections with no effective antibacterial agents? What can we do?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010, 28, 577-579.	0.5	7
335	Current management of bloodstream infections. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 815-829.	4.4	27
336	Clinical Features and Molecular Epidemiology of CMY-type β -Lactamase-Producing <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2009, 48, 739-744.	5.8	45
337	Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. <i>Gut</i> , 2009, 58, 1654-1660.	12.1	23
338	Comment on: Redefining extended-spectrum β -lactamases: balancing science and clinical need. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 212-213.	3.0	18
339	<i>Escherichia coli</i> producing SHV-type extended-spectrum β -lactamase is a significant cause of community-acquired infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 781-784.	3.0	24
340	No differences in quality of life between men and women undergoing HIV antiretroviral treatment. Impact of demographic, clinical and psychosocial factors. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 943-952.	1.2	18
341	Eradication of an extensive outbreak in a neonatal unit caused by two sequential <i>Klebsiella pneumoniae</i> clones harbouring related plasmids encoding an extended-spectrum β -lactamase. <i>Journal of Hospital Infection</i> , 2009, 73, 157-163.	2.9	30
342	Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant <i>Staphylococcus aureus</i> in Spain. <i>Clinical Microbiology and Infection</i> , 2009, 15, 1111-1118.	6.0	37

#	ARTICLE	IF	CITATIONS
343	Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Infection</i> , 2009, 58, 131-137.	3.3	50
344	Genetic Variability among <i>ampC</i> Genes from <i>Acinetobacter</i> Genomic Species 3. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1177-1184.	3.2	21
345	A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 682-690.	5.8	415
346	Long-term control of hospital-wide, endemic multidrug-resistant <i>Acinetobacter baumannii</i> through a comprehensive "bundle" approach. <i>American Journal of Infection Control</i> , 2009, 37, 715-722.	2.3	88
347	Epidemiology and Clinical Features of Community-Acquired, Healthcare Associated and Nosocomial Bloodstream Infections in Tertiary and Community Hospitals. <i>Clinical Microbiology and Infection</i> , 2009, 16, 1408-13.	6.0	68
348	Extended-spectrum β -lactamases in ambulatory care: a clinical perspective. <i>Clinical Microbiology and Infection</i> , 2008, 14, 104-110.	6.0	52
349	Risk-factors for emerging bloodstream infections caused by extended-spectrum β -lactamase-producing <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2008, 14, 180-183.	6.0	95
350	Biofilm formation in <i>Acinetobacter baumannii</i> : associated features and clinical implications. <i>Clinical Microbiology and Infection</i> , 2008, 14, 276-278.	6.0	196
351	Clinical significance of extended-spectrum β -lactamases. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 671-683.	4.4	136
352	Multidrug-resistant <i>Acinetobacter baumannii</i> : "Eyes Wide Shut". <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2008, 26, 185-186.	0.5	8
353	Update on infections in ICU patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2008, 26, 39-48.	0.5	0
354	Faecal carriage of extended-spectrum β -lactamase-producing <i>Escherichia coli</i> : prevalence, risk factors and molecular epidemiology. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1142-1149.	3.0	190
355	Neonatal sepsis caused by a CTX-M-32-producing <i>Escherichia coli</i> isolate. <i>Journal of Medical Microbiology</i> , 2008, 57, 1303-1305.	1.8	14
356	Community Infections Caused by Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> . <i>Archives of Internal Medicine</i> , 2008, 168, 1897.	3.8	333
357	Errata concerning Volume 14, Supplement 1, January 2008. <i>Clinical Microbiology and Infection</i> , 2008, 14, 293.	6.0	0
358	False extended-spectrum β -lactamase detection in <i>Acinetobacter</i> spp. due to intrinsic susceptibility to clavulanic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 301-308.	3.0	10
359	Update on vascular catheter-related infections. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 37-46.	0.5	1
360	P1349 Risk factors for ciprofloxacin resistance among ESBL-producing <i>Escherichia coli</i> isolated from non-hospitalised patients in Spain. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S374.	2.5	0

#	ARTICLE	IF	CITATIONS
361	P1652 Susceptibility of extended-spectrum β -lactamase-producing <i>Escherichia coli</i> strains causing nosocomially- and community-acquired bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S467.	2.5	0
362	Analysis of plasmids encoding extended-spectrum β -lactamases (ESBLs) from <i>Escherichia coli</i> isolated from non-hospitalised patients in Seville. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 89-92.	2.5	17
363	Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. <i>Hepatology</i> , 2007, 46, 622-630.	7.3	192
364	Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 171-176.	2.0	21
365	A Change in the Epidemiology of Infections Due to Extended-Spectrum β -Lactamase-Producing Organisms. <i>Clinical Infectious Diseases</i> , 2006, 42, 935-937.	5.8	65
366	Bacteremia Due to Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> in the CTX-M Era: A New Clinical Challenge. <i>Clinical Infectious Diseases</i> , 2006, 43, 1407-1414.	5.8	251
367	Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 671-678.	2.4	46
368	Nosocomial Bacteremia Due to an As Yet Unclassified <i>Acinetobacter</i> Genomic Species 17-Like Strain. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1587-1589.	3.9	8
369	Clinical and Molecular Epidemiology of Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> as a Cause of Nosocomial Infection or Colonization: Implications for Control. <i>Clinical Infectious Diseases</i> , 2006, 42, 37-45.	5.8	133
370	Long-term study of the frequency of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates producing extended-spectrum β -lactamases. <i>Clinical Microbiology and Infection</i> , 2005, 11, 625-631.	6.0	62
371	Risk-factors for the acquisition of imipenem-resistant <i>Acinetobacter baumannii</i> in Spain: a nationwide study. <i>Clinical Microbiology and Infection</i> , 2005, 11, 874-879.	6.0	102
372	Sam68 is tyrosine phosphorylated and recruited to signalling in peripheral blood mononuclear cells from HIV infected patients. <i>Clinical and Experimental Immunology</i> , 2005, 141, 518-525.	2.6	6
373	Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors. <i>Quality of Life Research</i> , 2005, 14, 1301-1310.	3.1	103
374	Colonization by high-level aminoglycoside-resistant enterococci in intensive care unit patients: epidemiology and clinical relevance. <i>Journal of Hospital Infection</i> , 2005, 60, 353-359.	2.9	10
375	Antimicrobial Susceptibility and Mechanisms of Resistance to Quinolones and β -Lactams in <i>Acinetobacter</i> Genospecies 3. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1430-1432.	3.2	17
376	Type 1 Integrons in Epidemiologically Unrelated <i>Acinetobacter baumannii</i> Isolates Collected at Spanish Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 364-365.	3.2	30
377	Cytomegalovirus mononucleosis as a cause of prolonged fever and prominent weight loss in immunocompetent adults. <i>Clinical Microbiology and Infection</i> , 2004, 10, 468-470.	6.0	6
378	Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> in Nonhospitalized Patients. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1089-1094.	3.9	395

#	ARTICLE	IF	CITATIONS
379	Clinical Features and Epidemiology of <i>Acinetobacter baumannii</i> Colonization and Infection in Spanish Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 819-824.	1.8	130
380	Diversidad clonal y sensibilidad a los antimicrobianos de <i>Acinetobacter baumannii</i> aislados en hospitales españoles. Estudio multicéntrico nacional: proyecto GEIH-Ab 2000. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2004, 22, 267-271.	0.5	15
381	Leptin stimulates the oxidative burst in control monocytes but attenuates the oxidative burst in monocytes from HIV-infected patients. <i>Clinical and Experimental Immunology</i> , 2003, 134, 464-469.	2.6	45
382	Bacteriemias por <i>Acinetobacter baumannii</i> : características clínicas y pronósticas. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2003, 21, 242-247.	0.5	10
383	Leishmaniasis visceral y tuberculosis peritoneal en un paciente con infección por el virus de la inmunodeficiencia humana. <i>Medicina Clínica</i> , 2003, 121, 357-358.	0.6	0
384	Clinical Epidemiology of <i>Stenotrophomonas maltophilia</i> Colonization and Infection. <i>Medicine (United States)</i> , 2003, 82, 1072-1077.	1.9	72
385	Leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells by in vitro activation and in vivo in HIV-infected patients. <i>Clinical and Experimental Immunology</i> , 2002, 129, 119-124.	2.6	56
386	Selection of empiric therapy in patients with catheter-related infections. <i>Clinical Microbiology and Infection</i> , 2002, 8, 275-281.	6.0	21
387	Nosocomial bacteremia due to <i>Acinetobacter baumannii</i> : epidemiology, clinical features and treatment. <i>Clinical Microbiology and Infection</i> , 2002, 8, 687-693.	6.0	246
388	Hospital infection control in Spain. <i>Journal of Hospital Infection</i> , 2001, 48, 258-260.	2.9	13
389	<i>Salmonella dublin</i> infection: a rare cause of spontaneous bacterial peritonitis and chronic colitis in alcoholic liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 587-589.	1.6	14
390	Kawasaki disease and parvovirus B19 infection in an adult HIV-1-infected patient. <i>Clinical Microbiology and Infection</i> , 1998, 4, 609-610.	6.0	11
391	Genotypic identification of an undescribed spotted fever group rickettsia in <i>Ixodes ricinus</i> from southwestern Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 1998, 58, 570-577.	1.4	56
392	Systemic Paradoxical Response to Antituberculous Drugs: Resolution with Corticosteroid Therapy. <i>Clinical Infectious Diseases</i> , 1997, 24, 517-519.	5.8	17
393	Azithromycin uptake by tissue cultured epithelial cells. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 293-295.	3.0	16
394	Doppler Transmitral Flow Pattern Is an Independent Prognostic Factor in Acute Myocardial Infarction. <i>Cardiology</i> , 1997, 88, 203-206.	1.4	9
395	<i>Corynebacterium jeikeium</i> osteomyelitis successfully treated with teicoplanin. <i>Journal of Infection</i> , 1997, 35, 325-326.	3.3	4
396	Delayed Tuberculin Reactivity in Indochinese Persons. <i>Annals of Internal Medicine</i> , 1997, 126, 661.	3.9	0

#	ARTICLE	IF	CITATIONS
397	Antimicrobial prophylaxis in surgery. <i>Plastic and Reconstructive Surgery</i> , 1987, 80, 329.	1.4	0
398	Duration of Treatment for <i>Pseudomonas aeruginosa</i> Bacteremia: a Retrospective Study. <i>Infectious Diseases and Therapy</i> , 0, , .	4.0	6